Business
Zura Bio Announces Participation at February Investor Conferences
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing
About this update from Zura Bio Limited
[{"type":"text","content":" HENDERSON, Nev.--(BUSINESS WIRE)--\nZura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in February.\n\n\nConference Details:\n\n\nEvent: Oppenheimer 2024 Winter CEO and Investor Summit\nDetails: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in 1x1 investor meetings from February 5 - 8, 2024, in Vail, CO.\n\n\nEvent: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference\nDetails: Robert Lisicki, President and Chief Operating Officer, will participate in a company presentation and investor 1x1 meetings on February 7 – 8, 2024, in New York, NY. The company presentation is currently scheduled for Wednesday, February 7, 2024 at 3:00 p.m. EST.\n\n\nEvent: Oppenheimer 34th Annual Healthcare Life Sciences Conference\nDetails: Robert Lisicki, President and Chief Operating Officer, and Kiran Nistala, M.D., Ph.D., Chief Medical Officer and Head of Development, will participate in a virtual company presentation and investor 1x1 meetings on February 13 - 14, 2024. The company presentation is currently scheduled for Tuesday, February 13, 2024 at 8:00 a.m. EST.\n\n\nEvent: Piper Sandler TSLP Biology Day\nDetails: Kiran Nistala, M.D., Ph.D., Chief Medical Officer and Head of Development, and Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will be participating in a virtual discussion on thymic stromal lymphopoietin (TSLP) science and its current landscape on Friday, February 23, 2024 at 9:00 – 9:30 a.m. EST.\n\n\nLinks for live webcasts and replays, if available, will be posted on the News & Events page in the Investors section of the Zura Bio website. Presentations will be archived on the website for at least 30 days following the event.\n\n\nABOUT ZURA BIO\n\n\nZura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (...